investors

ME Therapeutics Inc. was founded in September of 2014 with the goal of discovering and developing myeloid cell targeted immuno oncology drugs candidates

ME Therapeutics Inc completed a financing round and received advisory and financial support from NRC-IRAP to begin the discovery of novel anti-G-CSF antibody candidates for therapeutic development.

ME Therapeutics Inc. discovered several high affinity lead anti-G-CSF antibody candidates and initiated its first high throughput small molecule screen to search for small molecule drugs capable of reversing the negative effects tumour cells have on dendritic cell development. The Company also completed a financing round and received further advisory and funding support from NRC-IRAP.

ME Therapeutics Inc. worked together with the NRC to successfully humanize its lead anti-G-CSF antibody candidate. A provisional patent was filed on its lead antibody candidates and their use to treat cancer. ME Therapeutics Inc. entered into an assignment agreement with the University of British Columbia to acquire 100% of the rights to the G-CSF antibody patent.  In addition, ME Therapeutics Inc. initiated a second high throughput small molecule screen designed to discover small molecule drug candidates that could overcome the suppression of cancer killing T cells by tumour-derived myeloid cells. The Company also received further funding advisory and funding support from NRC-IRAP to further develop its anti-G-CSF antibody candidate.

ME Therapeutics Inc. worked with the NRC to develop a stable pool of anti-G-CSF antibody producing cells for potential future GMP production. The Company also continued in vitro and in vivo testing of the various small molecule drug candidates which it discovered through the two high throughput screening programs and completed a financing round to support research and development.

ME Therapeutics Inc. was the sole Canadian company invited to participate in the Massachusetts Institute of Technology (MIT) Idea2 incubator program where it received mentorship support to advance corporate development. The company also participated in a grant from the Michael Smith Foundation for Health Research which was awarded to Dr. Ken Harder to further advance the company’s anti-G-CSF antibody candidate. The company received further advisory and financial support from NRC-IRAP for its G-CSF antibody program.

Due to the COVID-19 pandemic, ME Therapeutics Inc., closed its lab facility at the University of British Columbia and moved to a contract research model. The Company applied to the Strategic Innovation Fund for Canada to support the development of its lead anti-G-CSF antibody candidate to potentially treat acute respiratory distress syndrome (ARDS) which was a major cause of COVID-19 related morbidity.

ME Therapeutics Inc. prioritized its existing data to determine which small molecule drug candidates to advance into preclinical development. The Company decided that developing a method to target the small molecule drug candidates to myeloid cells in tumours would be important moving forward.

ME Therapeutics Inc. completed a convertible debt financing round and started its prodrug development program in collaboration with Integrated Nanotherapeutics Inc. The prodrug development program was designed to create lipid nanoparticle based prodrug versions of the Company’s lead small molecule drug candidate in order to improve delivery of the small molecule drug candidate to myeloid cells.

ME Therapeutics Inc. was granted a Chinese patent on its anti-G-CSF antibody candidate and published peer-reviewed scientific research on the role of G-CSF in colorectal cancer. ME Therapeutics Inc. completed a reverse takeover transaction of ME Therapeutics Holdings Inc. and started in vitro testing of its first prodrug candidate. The company also initiated the development and in-vitro testing of a second prodrug candidate. In October 2023, ME Therapeutics Holdings Inc. listed its shares on the Canadian Securities Exchange (CSE). Subsequently, the Company initiated the in vivo testing of its prodrug candidates and also initiated non-GLP toxicology studies of its lead anti-G-CSF antibody candidate.